Biovie (BIVI) Assets Average (2013 - 2026)
Biovie (BIVI) posted Assets Average of $20.0 million for Q1 2026, down 18.87% sequentially from $24.7 million in Q4 2025, and down 20.53% YoY from $25.2 million in Q1 2025.
Biovie (BIVI) Assets Average (2013 - 2026) Analysis & Trends
Biovie has reported Assets Average for 14 years, with the latest figure at $20.0 million in Q1 2026.
- Quarterly Assets Average fell 20.53% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (down 20.53% YoY) and the FY2025 annual result came in at $23.4 million, down 22.45% from the prior year.
- Assets Average slipped to $20.0 million in Q1 2026 per BIVI's latest filing, from $24.7 million in the prior quarter.
- Over five years, Assets Average peaked at $46.2 million in Q1 2023 and troughed at $20.0 million in Q1 2026.
- A 5-year average of $27.4 million and a median of $24.7 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average jumped 144.48% in 2022, then tumbled 42.34% in 2024.
- Over 5 years, Assets Average stood at $35.0 million in 2022, then tumbled by 35.4% to $22.6 million in 2023, then rose by 3.72% to $23.5 million in 2024, then climbed by 5.09% to $24.7 million in 2025, then decreased by 18.87% to $20.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $20.0 million, $24.7 million, and $24.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 19.82 Bn |
| 10 | Biovie | 17.07 Mn | 17.07 Mn | - | 15.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.88 Mn |
| Mar 31, 2026 | 20.01 Mn |
| Dec 31, 2025 | 24.66 Mn |
| Sep 30, 2025 | 24.19 Mn |
| Jun 30, 2025 | 23.11 Mn |
| Mar 31, 2025 | 25.18 Mn |
| Dec 31, 2024 | 23.47 Mn |
| Sep 30, 2024 | 23.22 Mn |
| Jun 30, 2024 | 28.49 Mn |
| Mar 31, 2024 | 26.63 Mn |
| Dec 31, 2023 | 22.63 Mn |
| Sep 30, 2023 | 29.43 Mn |
| Jun 30, 2023 | 40.14 Mn |
| Mar 31, 2023 | 46.19 Mn |
| Dec 31, 2022 | 35.03 Mn |
| Sep 30, 2022 | 21.49 Mn |
| Jun 30, 2022 | 23.15 Mn |
| Mar 31, 2022 | 29.03 Mn |
| Dec 31, 2021 | 26.93 Mn |
| Sep 30, 2021 | 14.01 Mn |